Anavex Life Sciences Reports Data Review by the Independent Data Safety Monitoring Board for its Phase 2b/3 Clinical Trial of ANAVEX®2-73 in Patients with Alzheimer’s Disease

Anavex Life Sciences Reports Data Review by the Independent Data Safety Monitoring Board for its Phase 2b/3 Clinical Trial of ANAVEX®2-73 in Patients with Alzheimer’s Disease NEW YORK – March 31, 2021 – Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative…

Anavex Life Sciences Reports ANAVEX®2-73 (blarcamesine) featured as a Disease-Modifying Small Molecule in Phase 3 Clinical Trials in a New Publication in Medical Journal titled “Future Avenues for Alzheimer’s Disease Detection and Therapy”

Anavex Life Sciences Reports ANAVEX®2-73 (blarcamesine) featured as a Disease-Modifying Small Molecule in Phase 3 Clinical Trials in a New Publication in Medical Journal titled “Future Avenues for Alzheimer’s Disease Detection and Therapy”   NEW YORK – March 16, 2021 – Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company…

Anavex Life Sciences Reports Fiscal 2021 First Quarter Financial Results And Business Outlook  

Anavex Life Sciences Reports Fiscal 2021 First Quarter Financial Results And Business Outlook Conference Call and Webcast Today at 4:30 p.m. ET   NEW YORK – February 11, 2021 – Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including…

Anavex Life Sciences to Announce Fiscal 2021 First Quarter Financial Results and Business Outlook on Thursday, February 11, 2021

Anavex Life Sciences to Announce Fiscal 2021 First Quarter Financial Results and Business Outlook on Thursday, February 11, 2021 Conference Call and Webcast To be Held Thursday, February 11, 2021 4:30 pm Eastern Time NEW YORK – February 8, 2021 – Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company…

Anavex Life Sciences Reports Fiscal 2020 Year End Financial Results And Clinical Program Updates

Anavex Life Sciences Reports Fiscal 2020 Year End Financial Results  And Clinical Program Updates   Conference Call and Webcast Today at 4:30 p.m. ET   NEW YORK – December 28, 2020 – Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and…

Anavex Life Sciences to Announce Fiscal 2020 Year End Financial Results December 28th, 2020

Anavex Life Sciences to Announce Fiscal 2020 Year End Financial Results December 28th, 2020 Conference Call and Webcast To be Held Monday, December 28th, 2020 4:30 pm Eastern Time   NEW YORK – December 22, 2020 – Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the…

Proof of Concept Controlled Phase 2 Clinical Trial Data Evaluating ANAVEX®2-73 (blarcamesine) in Parkinson’s Disease Dementia Presented at CTAD 2020 Conference

Proof of Concept Controlled Phase 2 Clinical Trial Data Evaluating ANAVEX®2-73 (blarcamesine) in Parkinson’s Disease Dementia Presented at CTAD 2020 Conference   Statistically significant improvements in CDR system Cognitive Domain of Attention assessed by Choice Reaction Time (p = 0.039) and Digital Vigilance (p = 0.008) Statistically significant dose-dependent improvements in Episodic Memory (p =…

Anavex Life Sciences Receives Regulatory Approval from Health Canada and UK MHRA Expanding Phase 2b/3 ANAVEX®2-73 (blarcamesine) into Multinational Clinical Trial for Alzheimer’s Disease

Anavex Life Sciences Receives Regulatory Approval from Health Canada and UK MHRA Expanding Phase 2b/3 ANAVEX®2-73 (blarcamesine) into Multinational Clinical Trial for Alzheimer’s Disease   NEW YORK – June 4, 2020 – Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and…

Anavex Life Sciences Announces Publication of Clinical Data for ANAVEX®2-73 (blarcamesine) in Alzheimer’s Disease

Anavex Life Sciences Announces Publication of Clinical Data for ANAVEX®2-73 (blarcamesine) in Alzheimer’s Disease Published in Alzheimer’s & Dementia Journal, Results Highlight ANAVEX®2-73 (blarcamesine) Clinical Study, the First Reported Genome-Wide Search for Biomarkers Associated with Drug Response in Alzheimer’s Disease Clinically Meaningful Biomarkers Identified in ANAVEX®2-73 (blarcamesine) Studies Demonstrate a Significant Impact on Clinical Outcomes…

Anavex Life Sciences Provides Update on Clinical Program Development as Response to COVID-19

Anavex Life Sciences Provides Update on Clinical Program Development as Response to COVID-19   NEW YORK – March 31, 2020 – Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’s disease, Parkinson’s disease, Rett syndrome and other…